FDA advisory committee

FDA
Pharma

Exelixis' Cabometyx to face FDA adcomm in neuroendocrine tumors

The agency's Oncologic Drugs Advisory Committee is set to weigh in on the treatment in March ahead of the FDA's planned decision date of April 2025.
Zoey Becker Nov 27, 2024 11:30am
AZ

FDA raises safety flags ahead of adcomm for AZ's Andexxa

Nov 20, 2024 8:33am
Image of a neon sign with the word no lit up next to an unlit yes

FDA shoots down Intercept's bid for full approval of Ocaliva

Nov 12, 2024 2:12pm
FDA

Experts back FDA's plan to restrict PD-1 drugs in GI cancers

Sep 26, 2024 1:38pm
FDA

FDA challenges broad use of PD-1 drugs in stomach cancer

Sep 24, 2024 2:30pm
liver doctor liver disease

Intercept's Ocaliva nod in danger after negative FDA adcomm vote

Sep 16, 2024 10:40am